Altice USA Sets Sights on $3.4 Billion Adjusted EBITDA by 2025

Published 12 hours agoATUS

Altice USA Sets Sights on $3.4 Billion Adjusted EBITDA by 2025

Altice USA has revealed ambitious financial goals for 2025, targeting an adjusted EBITDA of $3.4 billion. This objective is primarily fueled by the company's expansion in its fiber and mobile sectors, marking a strategic push to bolster its offerings in high-demand areas.

In 2024, Altice USA reported a revenue of $8.95 billion and an operating income of $1.68 billion. This robust financial performance sets the stage for the company's growth strategy in the coming years. According to information available on Wikipedia, these figures highlight the company's steady financial footing as it seeks to make significant gains in the fiber and mobile markets.

As of May 9, 2025, Altice USA's stock is trading at $2.77 per share, a rise of 4.55% from the previous close. By aligning its strategy with growing industry trends that prioritize high-speed internet and mobile connectivity, Altice USA hopes to strengthen its position in these competitive markets.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Phathom Pharmaceuticals Sees Stock Surge on Director's Key Purchase

Phathom Pharmaceuticals Sees Stock Surge on Director's Key Purchase

7 minutes agoPHAT

Phathom Pharmaceuticals' stock saw a notable rise following a significant purchase by one of its directors. On December 13, 2024, Director Frank Karbe bought 12,500 shares at an average price of $7.93 each, totaling $99,125. This acquisition increased his total holdings to 57,000 shares, indicating strong insider confidence in the company's prospects, as reported by MarketBeat. The market responded positively to the insider buying activity, with Phathom's stock opening at $8.45 on December 16, 2024, up from the previous close of $7.89. The positive sentiment was further amplified by analysts at HC Wainwright and Needham & Company LLC, who both maintained a "buy" rating with a price target of $28.00, underscoring their optimism in the company's future. Beyond stock movements, Phathom Pharmaceuticals recently reported net revenue of $16.4 million for its drug Voquezna, exceeding analyst expectations. This growth was driven by the treatment of Erosive Esophagitis and expanded indications. Furthermore, the company has initiated strategic measures, including filing a Citizen's Petition with the FDA to align the exclusivity period for its VOQUEZNA tablets with its Dual and Triple Pak treatments, aiming to extend its market exclusivity for 10 years, as noted by Investing.com.

Pinterest Stock Soars as Revenue Forecast Exceeds Estimates

Pinterest Stock Soars as Revenue Forecast Exceeds Estimates

22 minutes agoPINS

Pinterest's latest announcement regarding its second-quarter revenue forecast has invigorated investor sentiment, resulting in a notable rise in the company's stock price. The company projects its Q2 revenue to range from $960 million to $980 million, surpassing Wall Street's average estimate of $966.3 million, as reported by Reuters. Following this optimistic guidance, Pinterest's shares jumped over 12% in pre-market trading. This surge showcases the confidence investors hold in Pinterest's potential to capitalize on growing advertising investments. Alongside this, the company reported a substantial 10% year-over-year growth in global monthly active users, now totaling 570 million, exceeding analyst expectations. Pinterest attributes its positive outlook to strategic enhancements such as the integration of artificial intelligence for personalizing ad campaigns. This focus has not only bolstered user engagement but also attracted advertisers aiming to tap into Gen Z audiences. As a result, the company's emphasis on direct response advertising continues to thrive, compensating for softer brand awareness spending.

The Trade Desk Expands Growth with Kokai Platform and Programmatic Advertising

The Trade Desk Expands Growth with Kokai Platform and Programmatic Advertising

37 minutes agoTTD

The Trade Desk has seen a significant boost in its financial performance, largely due to the successful adoption of its Kokai platform and an expanding share in the programmatic advertising market. Kokai, described as The Trade Desk's largest platform upgrade, has resulted in improved campaign performance metrics for its clients. Users of Kokai have reported over a 70% increase in incremental reach, a 27% improvement in cost per acquisition, and a 30% rise in data elements per impression, leading to more precise and cost-efficient advertising strategies. Simultaneously, The Trade Desk has experienced a 27% year-over-year revenue growth in the third quarter of 2024, reaching $628 million. This growth reflects the company's strengthening presence in the digital advertising sector. According to PPC Land, The Trade Desk's concentration on programmatic advertising, especially within the Connected TV segment, has been a crucial factor in this upward trend. Strategic alliances with major media companies like Spotify and Roku have further reinforced its foothold in the market. Overall, the integration of the Kokai platform and The Trade Desk's proactive strategies in the programmatic advertising landscape have significantly bolstered its financial achievements and market presence. These developments highlight the company's focus on delivering innovative solutions and establishing strong industry partnerships.

CrowdStrike Under Federal Scrutiny for Controversial Deal

CrowdStrike Under Federal Scrutiny for Controversial Deal

52 minutes agoCRWD

CrowdStrike Holdings Inc. is facing an investigation by the U.S. Department of Justice and the Securities and Exchange Commission over a $32 million deal with Carahsoft Technology Corp. The deal was meant to supply cybersecurity tools to the IRS, although the IRS did not end up purchasing the products. Bloomberg Law reported that this issue has caught the attention of federal authorities. The investigation is particularly focused on the timing of the transaction, which was completed on the last day of a fiscal quarter in 2023. This timing has raised concerns about how CrowdStrike recognized the revenue, leading to further scrutiny. According to Computerworld, the timing could suggest potential issues with revenue recognition policies, a critical aspect for publicly traded companies. Despite the ongoing investigation, CrowdStrike has publicly stated it stands by its accounting practices for the deal with Carahsoft and is cooperating with the authorities. Meanwhile, the company’s stock has been feeling the pressure, recently trading at $410.32, a drop of $18.31 from the previous close, as the market reacts to the unfolding situation. CrowdStrike urged investors to stay informed, indicating the investigation's outcome could carry significant weight for the firm.